Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric Population and Increasing Incidence of Chronic Diseases
4.2.2 Surging investment in Research and Development
4.3 Market Restraints
4.3.1 Pricing Pressure on the Companies by the Government
4.3.2 Risk factors associated with Corticosteriods on Prolonged use
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Glucocorticoids
5.1.2 Mineralocorticoids
5.2 By Route of administration
5.2.1 Topical steroids
5.2.2 Inhaled steroids
5.2.3 Oral forms
5.2.4 Systemic forms
5.2.5 Others
5.3 By Application
5.3.1 Rheumatology indications
5.3.2 Skin allergies
5.3.3 Endocrinology
5.3.4 Gastroenterology
5.3.5 Acute respiratory diseases
5.3.6 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 Sanofi S.A.
6.1.4 GlaxoSmithKline plc
6.1.5 Cipla Inc.
6.1.6 Johnson & Johnson Services, Inc.
6.1.7 AstraZeneca plc
6.1.8 Merck & Co., Inc.,
6.1.9 Sumitomo Corporation
6.1.10 Leo Pharma
6.1.11 Bayer Pharmaceutical


7 MARKET OPPORTUNITIES AND FUTURE TRENDS